Systematic echocardiography is not efficacious when screening an ethnically diverse cohort of athletes in West Asia. (29th August 2020)

• Record Type: Journal Article
• Authors: Riding, Nathan R; Sharma, Sanjay; Salah, Othman; Khalil, Nelly; Carré, François; George, Keith P; Hamilton, Bruce; Chalabi, Hakim; Whyte, Gregory P; Wilson, Mathew G
• Is Part Of: European journal of preventive cardiology. Volume 22:Number 2(2015)
• Page Start: 263
• Page End: 270
• Publication Date: 2020-08-29
• Subjects: Cost-effectiveness -- echocardiography -- pre-participation screening -- sudden cardiac death; Cardiovascular system -- Diseases -- Prevention -- Periodicals; Cardiac patients -- Rehabilitation -- Periodicals; 616.12
• DOI: 10.1177/2047487313506549
• Languages: English
• ISSNs: 2047-4873

Abstract

Abstract: Background: The clinical and economic value of including systematic echocardiography (ECHO) alongside the 12-lead electrocardiograpm (ECG) when undertaking pre-participation screening in athletes has not been examined, yet several sporting organistations recommend its inclusion. Design: To examine the efficacy of systematic ECHO alongside the ECG, to identify sudden cardiac death (SCD) disease and to provide a cost-analysis of a government-funded pre-participation screening programme. Methods: A total 1628 athletes presented for cardiological consultation, ECG, and ECHO as standard, with further cardiac examinations performed if necessary to confirm or exclude pathology. The efficacy of systematic ECHO was compared to an ECG-led programme, with ECHO reserved as a follow-up examination. Results: To screen 1628 athletes with ECG and ECHO cost US$743, 996. There were 54 24-h-blood pressure/ECG Holter recordings, 62 exercise tests, 25 CMRs, two electrophysiological studies, and two genetic tests, which cost US$67, 734: total US$811, 730. Eight athletes (0.5%) were identified with hypertrophic cardiomyopathy (HCM) and two (0.1%) with Wolff–Parkinson–White syndrome. The cost per identifed athlete was US$81, 173. All 10 athletes presented an abnormal ECG. No athlete diagnosed with HCM was identified by ECHO in isolation. When adopting a ECG-led screening protocol, 15% of athletes required ECHO as a follow-up examination, resulting in a US$380, 600 cost reduction (47% saving), with the cost per diagnosis reduced to US$43, 113. Conclusions: Athletes diagnosed with a disease associated with SCD were identified via an abnormal ECG and/or physical examination, personal symptoms, or family history. Screening athletes with systematic ECHO is not economically or clinically effective.